DP
NRIX icon

Diadema Partners’s Nurix Therapeutics NRIX Stock Holding History

Diadema Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95M Buy
+121,539
New +$2.07M 0.37% 61

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Diadema Partners's NRIX Position: Q2 2026 in Review

Diadema Partners opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 121,539 shares worth $2.95M. The stake represents 0.37% of the portfolio and ranks #61 among its holdings.

211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Diadema Partners held 121,539 shares of Nurix Therapeutics worth $2.95M as of Q2 2026.
  • Nurix Therapeutics was a new Diadema Partners position in Q2 2026.
  • Nurix Therapeutics made up 0.37% of Diadema Partners's portfolio in Q2 2026, its #61 holding.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.